Development of an Economical, Single Step Synthesis of FAZA, a Clinical Hypoxia Marker, and Potential Synthons to Prepare its Positional Analogs

Authors: Kumar, P.; Emami, S.; McEwan, A. J.B.; Wiebe, L. I.

Source: Letters in Drug Design & Discovery, Volume 6, Number 1, January 2009 , pp. 82-85(4)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

F-18 analog of 1-α-D-(5'-deoxy-5'-fluoro-(1S,2R,3S,4S) arabinofuranosyl)-2-nitroimidazole (FAZA) is a clinical PET tracer for diagnosing hypoxic tumors in cancer patients. Original synthesis of FAZA is lengthy, expensive and low yielding (∼12%). Current procedure is fast, economical, and affords FAZA (25%) in a single step, along with three useful synthons, 3, 4 and 5, to prepare other positional analogues of FAZA. Their chemical ratio depends on the solvent and reaction conditions.

Keywords: Azomycin nucleoside; Hypoxia sensitizer; FAZA; One step synthesis; Synthons; Solvents' effect

Document Type: Research article

DOI: http://dx.doi.org/10.2174/157018009787158616

Publication date: 2009-01-01

More about this publication?

Letters in Drug Design & Discovery publishes original letters on all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis will be on publishing quality papers very rapidly. Letters will be processed rapidly by taking full advantage of Internet technology for both the submission and review of manuscripts. The journal is essential reading to all pharmaceutical scientists involved in research in drug design and discovery.